BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics (TNGX)Tango TherapeuticsCompany update

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500

Related news

TNGXTango Therapeutics2026-09-01 11:00 EST

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-09-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-09-04 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-09-01 21:15 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-08-28 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-08-10 20:01 EST

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-09-03 20:05 EST

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNGXTango Therapeutics2026-09-01 11:00 EST

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Stock data

Close
21.75 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States